WO2014058329A8 - Kompositionen auf basis von hormonen der hypophyse, zur zugabe in infusionsflüssigkeiten - Google Patents
Kompositionen auf basis von hormonen der hypophyse, zur zugabe in infusionsflüssigkeiten Download PDFInfo
- Publication number
- WO2014058329A8 WO2014058329A8 PCT/PL2013/000118 PL2013000118W WO2014058329A8 WO 2014058329 A8 WO2014058329 A8 WO 2014058329A8 PL 2013000118 W PL2013000118 W PL 2013000118W WO 2014058329 A8 WO2014058329 A8 WO 2014058329A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluids
- metal compounds
- sterile conditions
- under sterile
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Gegenstand der Erfindung ist eine den Infusionsflüssigkeiten, insbesondere den Flüssigkeiten für Transplantation, dem Blutplasma, den bei Infusion oder Dialyse der zur Transplantation verwendeten Nieren benutzten Flüssigkeiten sowie den Blut- und blutstämmigen Präparaten und den in der Peritonealdialyse verwendeten Flüssigkeiten zugegebene Komposition. Die Komposition enthält Hormone: Prolaktin in Menge 1,0 ng/1 ÷ 10,0 μg/l, oder Somatotropin in Menge 10,0 ng/1 ÷ 10,0 μg/l oder Choriogonadotropin in Menge 1,0 ng/1÷ 1,0 μg/i oder Lutropin in Menge 10,0 ng/1 - 100,0 μg/l oder Folikulotropin in Menge 0,01 ng/1 ÷ 1,0 μg/l oder Buserelin in Menge 0.001 μg/l ÷ 1,0 μg/l. Eine Variante ist die Komposition, die entsprechend der Erfindung, die Metallverbindungen wie: Selen, Mangan oder Zink in Menge 0,01 μg/l ÷ 10,0 μg/l enthält. Das Hormon und die Metallverbindungen wie: Selen, Mangan oder Zink sind in Menge der 1÷5% igen Lösung der Askorbinsäure unter keimfreien Verhältnissen mit pH nicht über 3,5 oder in der 1÷5% igen Lösung der L- Zy stein unter keimfreien Verhältnissen mit pH nicht über 3,5 aufgelöst. Das in der Askorbinsäure - oder Zysteinlösung aufgelöste Hormon und die Metallverbindungen, unter keimfreien Verhältnissen in Phiolen vorbereitet, werden den bekannten Flüssigkeiten vor deren Gebrauch zugegeben.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13780230.2A EP2906234A1 (de) | 2012-10-09 | 2013-09-20 | Kompositionen auf basis von hormonen der hypophyse, zur zugabe in infusionsflüssigkeiten |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP.401116 | 2012-10-09 | ||
| PL401116A PL401116A1 (pl) | 2012-10-09 | 2012-10-09 | Kompozycja dodawana do płynów infuzyjnych |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2014058329A1 WO2014058329A1 (de) | 2014-04-17 |
| WO2014058329A8 true WO2014058329A8 (de) | 2014-12-31 |
Family
ID=49474668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/PL2013/000118 WO2014058329A1 (de) | 2012-10-09 | 2013-09-20 | Kompositionen auf basis von hormonen der hypophyse, zur zugabe in infusionsflüssigkeiten |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2906234A1 (de) |
| PL (1) | PL401116A1 (de) |
| WO (1) | WO2014058329A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014180959A1 (en) * | 2013-05-08 | 2014-11-13 | Gambro Lundia Ab | Dialysis formulation |
| PL236896B1 (pl) * | 2017-12-18 | 2021-02-22 | Biochefa Farmaceutyczny Zakl Naukowo Produkcyjny Spolka Z Ograniczona Odpowiedzialnoscia | Płyn do perfuzji i prezerwacji narządów i sposób jego wytwarzania |
| CN112569340A (zh) * | 2020-12-31 | 2021-03-30 | 苏州素仕生物科技有限公司 | 一种无菌布舍瑞林注射液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL205012A1 (pl) | 1978-03-01 | 1979-11-19 | Polski Komitet Normalizacji I | Sposob sprawdzania wag dzwigniowych o duzych obciazeniach oraz urzadzenie wzorcownicze do stosowania tego sposobu |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
| NZ526870A (en) * | 2001-01-25 | 2005-11-25 | Bristol Myers Squibb Co | Methods of administering epothilone analogs for the treatment of cancer |
| EP1812047A4 (de) | 2004-10-07 | 2010-08-04 | Stem Cell Therapeutics Corp | Stimulation der proliferation von pluripotential-stammzellen durch verabreichung von schwangerschaftsassoziierten verbindungen |
| WO2010084384A1 (en) * | 2009-01-26 | 2010-07-29 | Lola Maksumova | Combinations of an antiplatelet agent and an antioxidant for the treatment of vascular disorders |
| RU2423987C1 (ru) * | 2009-12-31 | 2011-07-20 | Государственное образовательное учреждение высшего профессионального образования САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ ХИМИКО-ФАРМАЦЕВТИЧЕСКАЯ АКАДЕМИЯ Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО СПХФА Росздрава) | Инфузионный раствор для восполнения объема циркулирующей крови, восстановления водно-электролитного баланса и нормализации процессов кроветворения |
-
2012
- 2012-10-09 PL PL401116A patent/PL401116A1/pl not_active IP Right Cessation
-
2013
- 2013-09-20 EP EP13780230.2A patent/EP2906234A1/de not_active Withdrawn
- 2013-09-20 WO PCT/PL2013/000118 patent/WO2014058329A1/de active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP2906234A1 (de) | 2015-08-19 |
| WO2014058329A1 (de) | 2014-04-17 |
| PL401116A1 (pl) | 2014-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| HK1214499A1 (zh) | 穩定的低粘度抗體配製品 | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| WO2012076670A3 (en) | Antibody formulation | |
| EA201490913A1 (ru) | Лекарственные формы для лечения сахарного диабета | |
| WO2011109365A3 (en) | Concentrated protein formulations and uses thereof | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| JP2017533218A5 (de) | ||
| MX2017012270A (es) | Composiciones sinergicas de acido dehidroacetico y metodos para reducir el amarillamiento en varias composiciones de usuario final. | |
| MY178249A (en) | Solid dialysis a agent containing alkali metal diacetate, and two-part type low-acetate dialysis agent using same | |
| WO2013112762A4 (en) | Bendamustine compositions and methods therefore | |
| ECSP066477A (es) | Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo | |
| PH12015500702B1 (en) | Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same | |
| WO2014058329A8 (de) | Kompositionen auf basis von hormonen der hypophyse, zur zugabe in infusionsflüssigkeiten | |
| MX2014013091A (es) | Composicion farmaceutica. | |
| WO2012012388A3 (en) | Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy | |
| AU2011208681A8 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | |
| ZA201504103B (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
| WO2012092305A3 (en) | Nanonized iron compositions and methods of use thereof | |
| MX341356B (es) | Composiciones ciclopolisacárido anionico-catiónico y bendamustina. | |
| BR112022004674A2 (pt) | Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas | |
| MX2009014178A (es) | Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa. | |
| WO2010021750A3 (en) | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer | |
| AR066943A1 (es) | Una composicion farmaceutica de melfalano | |
| WO2014055977A3 (en) | Modulation of branched amino acid concentrations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13780230 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2013780230 Country of ref document: EP |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |